Overview

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Status:
Completed

Trial end date:
2018-06-26

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Galapagos NV

Treatments:

Antirheumatic Agents